Short Interest in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Grows By 8.2%

Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) saw a large increase in short interest in January. As of January 15th, there was short interest totalling 3,840,000 shares, an increase of 8.2% from the December 31st total of 3,550,000 shares. Based on an average daily volume of 463,300 shares, the short-interest ratio is currently 8.3 days.

Aldeyra Therapeutics Stock Performance

Shares of Aldeyra Therapeutics stock traded up $0.30 on Wednesday, reaching $5.65. 221,939 shares of the company were exchanged, compared to its average volume of 322,298. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.18. Aldeyra Therapeutics has a 1-year low of $2.71 and a 1-year high of $6.55. The company's 50-day moving average is $5.03 and its two-hundred day moving average is $5.10.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last announced its earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) EPS for the quarter, hitting the consensus estimate of ($0.25). On average, equities research analysts forecast that Aldeyra Therapeutics will post -0.92 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. King Wealth Management Group boosted its stake in shares of Aldeyra Therapeutics by 24.5% in the 3rd quarter. King Wealth Management Group now owns 13,700 shares of the biotechnology company's stock valued at $74,000 after purchasing an additional 2,700 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in Aldeyra Therapeutics by 14.4% during the second quarter. The Manufacturers Life Insurance Company now owns 21,734 shares of the biotechnology company's stock worth $72,000 after purchasing an additional 2,729 shares during the period. SG Americas Securities LLC lifted its position in Aldeyra Therapeutics by 14.4% during the fourth quarter. SG Americas Securities LLC now owns 22,365 shares of the biotechnology company's stock worth $112,000 after acquiring an additional 2,822 shares during the last quarter. US Bancorp DE acquired a new position in shares of Aldeyra Therapeutics in the 3rd quarter valued at approximately $30,000. Finally, Captrust Financial Advisors raised its position in Aldeyra Therapeutics by 89.3% during the third quarter. Captrust Financial Advisors now owns 19,261 shares of the biotechnology company's stock valued at $104,000 after purchasing an additional 9,087 shares in the last quarter. 59.71% of the stock is owned by institutional investors.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.